Brief: AB Science Announces Masitinib Receives Orphan Drug Status For The Treatment Of Amyotrophic Lateral Sclerosis In Switzerland
27/12/2022 18:11
Dec 27 (Reuters) - AB Science SA ABS.PA :
* MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF
AMYOTROPHIC LATERAL SCLEROSIS IN SWITZERLAND
Source text for Eikon: ID:nGNE6wK71D
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease